Your browser is no longer supported. Please, upgrade your browser.
Settings
EBS Emergent BioSolutions Inc. daily Stock Chart
EBS [NYSE]
Emergent BioSolutions Inc.
Index- P/E35.64 EPS (ttm)1.96 Insider Own3.80% Shs Outstand50.95M Perf Week4.50%
Market Cap3.55B Forward P/E25.62 EPS next Y2.72 Insider Trans-12.97% Shs Float43.30M Perf Month13.99%
Income100.30M PEG2.35 EPS next Q0.57 Inst Own84.10% Short Float4.14% Perf Quarter14.57%
Sales705.50M P/S5.04 EPS this Y29.80% Inst Trans-0.12% Short Ratio4.74 Perf Half Y36.56%
Book/sh19.31 P/B3.61 EPS next Y25.44% ROA9.00% Target Price69.13 Perf Year82.28%
Cash/sh6.66 P/C10.47 EPS next 5Y15.15% ROE10.80% 52W Range37.89 - 71.77 Perf YTD50.08%
Dividend- P/FCF13.47 EPS past 5Y20.60% ROI9.60% 52W High-1.84% Beta1.24
Dividend %- Quick Ratio4.30 Sales past 5Y14.80% Gross Margin58.80% 52W Low85.93% ATR2.74
Employees1256 Current Ratio5.50 Sales Q/Q16.30% Oper. Margin18.70% RSI (14)62.51 Volatility4.62% 4.41%
OptionableYes Debt/Eq0.00 EPS Q/Q-38.80% Profit Margin14.20% Rel Volume0.41 Prev Close69.74
ShortableYes LT Debt/Eq0.01 EarningsNov 01 AMC Payout0.00% Avg Volume378.00K Price70.45
Recom2.00 SMA207.79% SMA509.28% SMA20025.70% Volume35,760 Change1.02%
Nov-02-18Upgrade Goldman Neutral → Buy
Aug-03-18Reiterated Chardan Capital Markets Buy $53 → $57
Jun-13-18Initiated Argus Buy $62
Apr-25-18Downgrade Wells Fargo Outperform → Market Perform
Jan-24-18Initiated Goldman Neutral
Jan-16-18Reiterated Chardan Capital Markets Buy $47 → $53
Jun-28-16Reiterated Singular Research Buy $44 → $40
Apr-15-16Initiated Chardan Capital Markets Buy $47
Mar-28-16Initiated Singular Research Buy $44
Feb-19-16Initiated Wells Fargo Outperform
May-15-14Initiated Summer Street Research Buy $35
May-31-11Reiterated WBB Securities Strong Buy $20.50 → $30
Jan-10-11Reiterated Wedbush Outperform $27 → $32
Nov-05-10Reiterated Wedbush Outperform $22 → $27
Aug-18-10Upgrade WBB Securities Buy → Strong Buy $20.50
Aug-06-10Reiterated Caris & Company Buy $25 → $23
Jul-14-10Upgrade WBB Securities Hold → Buy $15.60 → $20.50
May-06-10Downgrade WBB Securities Buy → Hold $15.60
Dec-28-09Reiterated Caris & Company Buy $17 → $19
Mar-23-09Reiterated Caris & Company Buy $25 → $21
Nov-20-18 09:10AM  Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint Zacks
Nov-19-18 05:05PM  Emergent-Valneva Zika vaccine clears early trial Reuters
04:22PM  Emergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus GlobeNewswire
04:16PM  EMERGENT BIOSOLUTIONS AND VALNEVA REPORT POSITIVE PHASE 1 RESULTS FOR THEIR VACCINE CANDIDATE AGAINST THE ZIKA VIRUS GlobeNewswire
Nov-09-18 11:27AM  Edited Transcript of EBS earnings conference call or presentation 1-Nov-18 9:00pm GMT Thomson Reuters StreetEvents
Nov-06-18 03:39PM  Emergent BioSolutions Nabs Its Acquisition (Times 2) Motley Fool
07:00AM  Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences GlobeNewswire
Nov-02-18 12:54PM  Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates Zacks
07:30AM  Emergent Biosolutions (EBS) Q3 Earnings and Revenues Lag Estimates Zacks
05:07AM  Emergent Biosolutions: 3Q Earnings Snapshot Associated Press
02:42AM  European markets rise on hopes of a US-China trade agreement; banks in the spotlight CNBC
Nov-01-18 09:33PM  Emergent BioSolutions Inc (EBS) Q3 2018 Earnings Conference Call Transcript Motley Fool
04:30PM  Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months of 2018 GlobeNewswire
02:06PM  Emergent BioSolutions defends opioid overdose drug against generic competitor American City Business Journals
09:49AM  What Should You Know About Emergent BioSolutions Incs (NYSE:EBS) Growth? Simply Wall St.
Oct-29-18 11:12AM  What's in Store for Sangamo (SGMO) This Earnings Season? Zacks
Oct-25-18 04:36PM  IBD Stock Of The Day Outperforms Biotech Sector In A Rough October Investor's Business Daily
01:47PM  Is Emergent BioSolutions Incs (NYSE:EBS) High P/E Ratio A Problem For Investors? Simply Wall St.
07:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within StoneMor Partners, Catalyst Biosciences, Kennametal, Emergent Biosolutions, Kimball International, and Tailored Brands New Research Emphasizes Economic Growth GlobeNewswire
Oct-24-18 02:30PM  Emergent BioSolutions to Offer All Public Libraries and YMCAs in the U.S. Free Opioid Awareness Education and NARCAN® (naloxone HCl) Nasal Spray GlobeNewswire
Oct-18-18 09:30AM  EBS or ALKS: Which Is the Better Value Stock Right Now? Zacks
Oct-16-18 01:23PM  Government wants drug companies to disclose prices on TV ads Yahoo Finance Video +5.06%
12:14PM  Emergent Completes Acquisition of Narcan Maker Adapt Pharma Zacks
Oct-15-18 04:30PM  Emergent BioSolutions Completes Acquisition of Adapt Pharma and Flagship Product Narcan® (Naloxone HCI) Nasal Spray GlobeNewswire
Oct-11-18 06:30AM  Emergent BioSolutions to Release Third Quarter 2018 Financial Results and Conduct a Conference Call on November 1, 2018 GlobeNewswire
Oct-09-18 01:04PM  Opioid antidote inventor: We're in the 'next phase of this opioid crisis' Yahoo Finance
Oct-05-18 05:40PM  [$$] Deal Close Announcements: Oct. 1-5 The Wall Street Journal
10:30AM  Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up Zacks
08:35AM  The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker Benzinga
Oct-04-18 06:27PM  Emergent BioSolutions Completes Acquisition of Specialty Vaccines Company PaxVax GlobeNewswire
Sep-17-18 08:00AM  Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Emergent BioSolutions ACCESSWIRE
Sep-06-18 08:15PM  Emergent Biosolutions Inc (EBS) CEO Daniel Abdun-nabi Sold $5.5 million of Shares GuruFocus.com
Sep-05-18 07:45AM  Factors of Influence in 2018, Key Indicators and Opportunity within Emergent Biosolutions, LGI Homes, Surgery Partners, Overseas Shipholding Group, National Commerce, and comScore New Research Emphasizes Economic Growth GlobeNewswire
Aug-29-18 03:07PM  Why Emergent BioSolutions is jumping into the opioid crisis with new acquisition American City Business Journals
02:08PM  New Narcan Owner Sees Schools as Growth Area for Overdose Spray Bloomberg
01:26PM  Is Emergent BioSolutions Inc (NYSE:EBS) Worth US$61.53 Based On Intrinsic Value? Simply Wall St.
11:14AM  Emergent (EBS) to Buy Narcan Maker Adapt Pharma for $735M Zacks
07:54AM  The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent Benzinga
Aug-28-18 06:50PM  Emergent BioSolutions to buy Narcan maker Adapt Pharma Reuters
06:30PM  Emergent BioSolutions to buy Narcan maker Adapt Pharma Reuters
06:08PM  Narcan Maker Adapt to Be Acquired by Emergent BioSolutions Bloomberg
04:58PM  Emergent BioSolutions to buy Adapt Pharma for up to $735 mln Reuters
04:49PM  Emergent BioSolutions agrees to buy Narcan spray maker Adapt Pharma for $735 million MarketWatch
04:31PM  Emergent BioSolutions Joins Effort to Combat National Public Health Threat From Opioid Overdose Through Acquisition of Adapt Pharma and Its Flagship Product NARCAN® (naloxone HCl) Nasal Spray GlobeNewswire
Aug-21-18 04:01PM  IBD Stock Of The Day: Vertex Pharma Nears Third Breakout Of 2018 Investor's Business Daily
Aug-17-18 07:00AM  Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences GlobeNewswire
Aug-16-18 11:25AM  Two Maryland biotechs get $36 million to aid in new vaccine development American City Business Journals
06:15AM  CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine GlobeNewswire
Aug-15-18 08:25AM  Report: Developing Opportunities within RA PHARMCTL INC, Oclaro, Emergent Biosolutions, Kennametal, Instructure, and Donegal Group Future Expectations, Projections Moving into 2018 GlobeNewswire
06:02AM  5 Promising Vaccines in Development -- and the Stocks Poised to Profit From Them Motley Fool
Aug-13-18 01:34AM  Edited Transcript of EBS earnings conference call or presentation 2-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Aug-09-18 08:06AM  [$$] Emergent BioSolutions Buys PaxVax for $270 Million The Wall Street Journal
06:36AM  Emergent BioSolutions to Acquire PaxVax from Cerberus Capital Management PR Newswire
06:30AM  Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax GlobeNewswire
Aug-07-18 04:04PM  Emergent BioSolutions Makes Up for Last Quarter Motley Fool
Aug-06-18 11:21AM  Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates Zacks
Aug-02-18 06:45PM  Emergent Biosolutions (EBS) Surpasses Q2 Earnings and Revenue Estimates Zacks
05:40PM  Emergent Biosolutions: 2Q Earnings Snapshot Associated Press
04:47PM  Erste CEO Sees ECB Rate Hike Towards End of 2019 Bloomberg Video
04:30PM  Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months of 2018 GlobeNewswire
Jul-31-18 04:30PM  Emergent BioSolutions Initiates Phase 1 Clinical Study of Zika Virus Immune Globulin Therapeutic GlobeNewswire
Jul-30-18 09:30AM  EBS vs. NEO: Which Stock Should Value Investors Buy Now? Zacks
Jul-18-18 04:30PM  Emergent BioSolutions to Release Second Quarter 2018 Financial Results and Conduct a Conference Call on August 2, 2018 GlobeNewswire
Jul-11-18 09:30AM  EBS vs. NEO: Which Stock Is the Better Value Option? Zacks
Jun-13-18 10:51AM  Argus: Anthrax Vaccine Maker Emergent BioSolutions Poised For Earnings Growth Benzinga
Jun-08-18 06:30AM  Emergent BioSolutions to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference GlobeNewswire
Jun-07-18 11:45AM  Emergent BioSolutions plans $50 million expansion to Baltimore facility American City Business Journals
06:30AM  Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility GlobeNewswire
May-29-18 07:40AM  Blog Exposure - Emergent BioSolutions and Profectus BioSciences Receive Contract from CEPI to Develop Nipah Virus Vaccine ACCESSWIRE
May-27-18 06:00PM  CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine GlobeNewswire
May-25-18 01:03AM  The latest outbreak of a deadly virus has scientists racing to create a vaccine Quartz
May-24-18 09:06AM  U.S. biotechs to speed work on Nipah vaccine as virus hits India Reuters
08:15AM  Consolidated Research: 2018 Summary Expectations for PGT, National Commerce, CrossAmerica Partners LP, Destination XL Group, Allegiance Bancshares, and Emergent Biosolutions Fundamental Analysis, Key Performance Indications GlobeNewswire
06:38AM  Global group taps U.S. biotechs to speed work on Nipah vaccine Reuters
06:11AM  CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine GlobeNewswire
May-10-18 04:50PM  Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 24, 2018 at 9:00 AM EDT; Webcast Will Be Available GlobeNewswire
May-08-18 04:43PM  Emergent BioSolutions Moves Things Around Motley Fool
May-07-18 05:54AM  Edited Transcript of EBS earnings conference call or presentation 3-May-18 9:00pm GMT Thomson Reuters StreetEvents
May-04-18 11:50AM  Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View Zacks
05:03AM  Emergent Biosolutions: 1Q Earnings Snapshot Associated Press
May-03-18 04:30PM  Emergent BioSolutions Reports First Quarter 2018 Financial Results GlobeNewswire
Apr-25-18 03:38PM  Emergent Biosolutions' Stock Run Can't Continue Forever, Wells Fargo Says In Downgrade Benzinga
Apr-19-18 06:30AM  Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018 GlobeNewswire
Apr-13-18 02:58PM  Emergent BioSolutions to enter 5 new countries with anthrax vaccine American City Business Journals
Apr-12-18 06:30AM  Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European Countries GlobeNewswire
06:30AM  Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorisation of BioThrax in European Countries Business Wire
Apr-06-18 06:32PM  Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why Zacks
Apr-02-18 08:10AM  New Research Coverage Highlights SITO Mobile, Emergent Biosolutions, Instructure, First Financial Bankshares, Jones Lang LaSalle, and QAD Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-26-18 04:30PM  Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Companys Growth Strategy GlobeNewswire
02:23AM  Why Is Emergent Biosolutions (EBS) Up 8% Since Its Last Earnings Report? Zacks
Mar-22-18 04:30PM  Emergent BioSolutions to Implement Stock Repurchase Program for up to $50 Million of Its Common Stock GlobeNewswire
Mar-21-18 05:16PM  Edited Transcript of EBS earnings conference call or presentation 22-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Mar-01-18 05:30AM  One Gaithersburg biotech's latest marketing push: Selling doomsday kits on Amazon American City Business Journals
Feb-28-18 06:45AM  Emergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin Program GlobeNewswire
Feb-26-18 04:16PM  EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS GlobeNewswire
02:51PM  Emergent BioSolutions Gets its Deals Done (and Expect More to Come) Motley Fool
Feb-23-18 10:38AM  Emergent (EBS) Q4 Earnings Beat Estimates, 2018 View Solid Zacks
05:00AM  Emergent Biosolutions beats 4Q profit forecasts Associated Press
Feb-22-18 01:00PM  Emergent BioSolutions Inc. to Host Earnings Call ACCESSWIRE
09:03AM  What You Must Know About Emergent BioSolutions Incs (NYSE:EBS) 12.20% ROE Simply Wall St.
Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Richard RonaldDirectorNov 07Option Exercise13.007,893102,60928,856Nov 08 05:14 PM
Zoon Kathryn CDirectorNov 07Sale69.744,242295,85618,643Nov 08 06:49 PM
Richard RonaldDirectorNov 07Sale70.007,893552,51020,963Nov 08 05:14 PM
JOULWAN GEORGE ADirectorNov 06Sale68.454,058277,78426,214Nov 08 04:36 PM
Harsanyi ZsoltDirectorNov 06Sale68.908,000551,19433,972Nov 08 04:34 PM
Havey AdamEVP, Business OperationsNov 02Option Exercise25.626,168158,02435,421Nov 05 05:03 PM
Havey AdamEVP, Business OperationsNov 02Sale64.506,168397,83629,253Nov 05 05:03 PM
Havey AdamEVP, Business OperationsNov 01Option Exercise25.622,01151,52231,264Nov 05 05:03 PM
Havey AdamEVP, Business OperationsNov 01Sale63.502,011127,69929,253Nov 05 05:03 PM
Havey AdamEVP, Business OperationsOct 17Option Exercise25.623148,04529,567Oct 19 05:06 PM
Havey AdamEVP, Business OperationsOct 17Sale61.5031419,31129,253Oct 19 05:06 PM
Havey AdamEVP, Business OperationsOct 16Option Exercise25.6210,005256,32835,418Oct 17 04:19 PM
Havey AdamEVP, Business OperationsOct 16Sale62.2710,005622,98829,253Oct 17 04:19 PM
Havey AdamEVP, Business OperationsOct 15Option Exercise25.6212,330315,89536,079Oct 17 04:19 PM
Havey AdamEVP, Business OperationsOct 15Sale60.1212,991781,03829,253Oct 17 04:19 PM
Abdun-Nabi DanielCEOSep 17Option Exercise13.381,31917,648167,886Sep 18 04:09 PM
Abdun-Nabi DanielCEOSep 17Sale65.001,31985,735166,567Sep 18 04:09 PM
Abdun-Nabi DanielCEOSep 14Option Exercise13.3828,220377,584194,787Sep 18 04:09 PM
Abdun-Nabi DanielCEOSep 14Sale65.0028,2201,834,300166,567Sep 18 04:09 PM
Abdun-Nabi DanielCEOSep 05Sale59.4930,7761,830,944166,567Sep 06 05:51 PM
Abdun-Nabi DanielCEOSep 04Option Exercise13.3860,000802,800257,343Sep 06 05:51 PM
Abdun-Nabi DanielCEOSep 04Sale60.5460,0003,632,286197,343Sep 06 05:51 PM
Richard RonaldDirectorAug 21Option Exercise14.717,793114,63528,756Aug 23 08:51 AM
Richard RonaldDirectorAug 21Sale60.027,793467,70920,963Aug 23 08:51 AM
El-Hibri FuadChairmanAug 14Sale56.5716,318923,1091,488,675Aug 15 04:25 PM
El-Hibri FuadChairmanAug 13Sale55.5020,0001,110,0001,504,993Aug 15 04:25 PM
Richard RonaldDirectorAug 03Option Exercise14.711001,47121,063Aug 23 08:51 AM
Richard RonaldDirectorAug 03Sale60.001006,00020,963Aug 23 08:51 AM
El-Hibri FuadChairmanJul 12Sale54.5015,000817,5521,524,993Jul 16 08:18 PM
El-Hibri FuadChairmanJul 09Sale53.6115,000804,1501,539,993Jul 11 05:05 PM
JOULWAN GEORGE ADirectorJun 11Sale52.895,000264,44830,272Jun 12 04:28 PM
Richard RonaldDirectorJun 06Sale53.007,342389,12620,963Jun 07 04:21 PM
Zoon Kathryn CDirectorJun 06Sale52.8137619,85722,885Jun 07 04:20 PM
Hauer Jerome MDirectorJun 05Sale52.168,375436,87612,588Jun 07 04:27 PM
Abdun-Nabi DanielChief Executive OfficerJun 05Sale52.1115,785822,615197,343Jun 07 05:07 PM
Zoon Kathryn CDirectorMay 24Sale51.151,37770,43423,261May 29 04:16 PM
Richard RonaldDirectorApr 17Option Exercise13.377,893105,52931,303Apr 19 04:49 PM
Richard RonaldDirectorApr 17Sale55.007,893434,11523,410Apr 19 04:49 PM
Havey AdamEVP, Business OperationsMar 12Sale52.825,842308,57429,914Mar 13 05:57 PM
Havey AdamEVP, Business OperationsMar 07Option Exercise22.036,573144,80339,573Mar 09 05:24 PM
Havey AdamEVP, Business OperationsMar 01Sale49.501,89893,95133,000Mar 01 05:03 PM
Hauer Jerome MDirectorJan 23Sale50.252,577129,49416,068Jan 24 08:22 PM
Hauer Jerome MDirectorJan 22Option Exercise25.475,152131,22123,797Jan 24 08:22 PM
Hauer Jerome MDirectorJan 22Sale50.915,152262,29218,645Jan 24 08:22 PM
Abdun-Nabi DanielPresident & CEOJan 02Option Exercise14.4421,906316,323226,040Jan 04 04:31 PM
Abdun-Nabi DanielPresident & CEOJan 02Sale47.9121,9061,049,516204,134Jan 04 04:31 PM
Abdun-Nabi DanielPresident & CEODec 13Option Exercise14.4420,000288,800224,134Dec 14 04:57 PM
Abdun-Nabi DanielPresident & CEODec 13Sale45.9920,000919,800204,134Dec 14 04:57 PM
Richard RonaldDirectorDec 12Option Exercise10.6423,681251,96647,091Dec 13 08:20 AM
Richard RonaldDirectorDec 12Sale45.0223,6811,066,22523,410Dec 13 08:20 AM
Harsanyi ZsoltDirectorDec 07Sale42.477,000297,29037,077Dec 11 08:25 AM
El-Hibri FuadChairmanNov 29Option Exercise22.0327,983616,4651,558,199Nov 30 11:29 AM
El-Hibri FuadChairmanNov 29Sale42.0827,9831,177,5251,530,216Nov 30 11:29 AM
El-Hibri FuadChairmanNov 28Option Exercise22.0320,000440,6001,550,216Nov 30 11:29 AM
El-Hibri FuadChairmanNov 28Sale41.5920,000831,8001,530,216Nov 30 11:29 AM